Study of Weekly LOC-paclitaxel Injection for Melanoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Melanoma
Interventions
DRUG

LOC-paclitaxel

"Phase I Starting Dose: 100 mg/m\^2 IV (intravenously) 1 hour infusion on Day 1, 8, 15, 22 and 29; and repeated every 42 days (6 weeks) per cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

American Regent, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01039844 - Study of Weekly LOC-paclitaxel Injection for Melanoma | Biotech Hunter | Biotech Hunter